Karthik Ramasamy

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8801341/publications.pdf

Version: 2024-02-01

145 papers	2,092 citations	257450 24 h-index	276875 41 g-index
148 all docs	148 docs citations	148 times ranked	2494 citing authors

#	Article	IF	Citations
1	Daratumumab Monotherapy for Heavily Pre-treated and Refractory Myeloma: Results from a UK Multicentre Real World Cohort. Journal of Oncology Pharmacy Practice, 2023, 29, 299-304.	0.9	2
2	COVID symptoms, testing, shielding impact on patientâ€reported outcomes and early vaccine responses in individuals with multiple myeloma. British Journal of Haematology, 2022, 196, 95-98.	2.5	13
3	Multiple myeloma screening within a fracture liaison service (FLS). Osteoporosis International, 2022, 33, 937-941.	3.1	3
4	Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phaseï»¿ 2 trial. Blood Cancer Journal, 2022, 12, 9.	6.2	14
5	Immune response to <scp>COVID</scp>â€19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent Tâ€cell response. British Journal of Haematology, 2022, 197, 293-301.	2.5	16
6	Anti-BCMA Immunotherapy in Myeloma: Is It the Tumor or the Immune System That Most Undermines Outcomes?. , 2022, 19, .		0
7	BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events. Expert Review of Hematology, 2022, 15, 503-517.	2.2	1
8	Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK-Wide Real-World Dataset. HemaSphere, 2022, 6, e738.	2.7	1
9	Generic Lenalidomide: An opportunity to address the balance of administrative burden and drug safety. European Journal of Haematology, 2022, 109, 305-306.	2.2	0
10	Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study. Hematology, 2022, 27, 691-699.	1.5	4
11	Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort. PLoS ONE, 2022, 17, e0270854.	2.5	6
12	Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood, 2021, 137, 232-237.	1.4	90
13	COVIDâ€19 and myeloma clinical research â€“ experience from the CARDAMON clinical trial. British Journal of Haematology, 2021, 192, e14-e16.	2.5	7
14	Myeloma clinical outcomes following the first wave of COVIDâ€19: results from the Thames Valley Cancer Alliance (UK). British Journal of Haematology, 2021, 192, e136-e139.	2.5	2
15	Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. Journal of Clinical Oncology, 2021, 39, 227-237.	1.6	22
16	Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer Journal, 2021, 11, 40.	6.2	46
17	Efficacy and tolerability of VCD chemotherapy in a UK realâ€world dataset of elderly transplantâ€ineligible newly diagnosed myeloma patients. European Journal of Haematology, 2021, 106, 563-573.	2.2	1
18	Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. British Journal of Haematology, 2021, 193, 750-760.	2.5	8

#	Article	IF	Citations
19	Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive). Haematologica, 2021, 106, 2694-2706.	3.5	6
20	Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial.. Journal of Clinical Oncology, 2021, 39, 8020-8020.	1.6	2
21	Management of patients with difficult-to-treat multiple myeloma. Future Oncology, 2021, 17, 2089-2105.	2.4	1
22	Improving the diagnostic pathway in patients presenting with acute kidney injury secondary to de novo multiple myeloma: a short report. BMJ Open Quality, 2021, 10, e001085.	1.1	3
23	Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clinical Cancer Research, 2021, 27, 5195-5212.	7.0	26
24	The management of Castleman disease. British Journal of Haematology, 2021, 195, 328-337.	2.5	8
25	Validation of clinicalâ€grade whole genome sequencing reproduces cytogenetic analysis and identifies mutational landscape in newlyâ€diagnosed multiple myeloma patients: A pilot study from the 100,000 Genomes Project. EJHaem, 2021, 2, 809.	1.0	3
26	Using quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify low level monoclonal proteins. Clinical Biochemistry, 2021, 95, 81-83.	1.9	5
27	A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma. Blood Cancer Journal, 2021, 11, 149.	6.2	5
28	Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options. Blood Reviews, 2021, 49, 100808.	5.7	27
29	Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (â‰¥2nd) Tj ETQq1 1 0.784314 rgBT /O 1396-1404.	1.3	5
30	Clinical features and diagnosis of multiple myeloma: a population-based cohort study in primary care. BMJ Open, 2021, 11, e052759.	1.9	0
31	OAB-003: CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S2-S3.	0.4	1
32	Efficacy Outcomes of Isatuximab with Pomalidomide and Dexamethasone Are Comparable to (ICARIA-MM) Trial Data: Initial Results of a UK-Wide Real-World Study of Relapsed Myeloma Patients. Blood, 2021, 138, 1963-1963.	1.4	1
33	Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the Connect Â® Multiple Myeloma (MM) Disease Registry. Blood, 2021, 138, 117-117.	1.4	2
34	Discovery of Prolyl-tRNA Synthetase As a Novel Target in Multiple Myeloma. Blood, 2021, 138, 890-890.	1.4	0
35	Upfront Autologous Stem Cell Transplantation (ASCT) Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Consolidation in Transplant-Eligible, Newly Diagnosed (NDTE) Multiple Myeloma (MM): Results of the Cardamon Study According to Cytogenetic Risk. Blood, 2021, 138, 2911-2911.	1.4	0
36	PET-CT for Assessment of Multiple Myeloma Disease Burden and Metabolic Response before and after Carfilzomib-Based Induction, Consolidation and Carfilzomib Maintenance Therapy: Data from the UK NCRI Cardamon Study. Blood, 2021, 138, 2750-2750.	1.4	0

#	Article	IF	Citations
37	The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice. Blood, 2021, 138, 2701-2701.	1.4	2
38	REALM (OP-RW001): Comparing the Characteristics and Clinical Outcomes of Patients with Relapsed/Refractory Multiple Myeloma in the Real World to Patients Receiving Melflufen in the Horizon Study. Blood, 2021, 138, 1967-1967.	1.4	0
39	A Clinically Validated Targeted Capture Panel to Identify Translocations, Copy Number Abnormalities, and Mutations in Multiple Myeloma. Blood, 2021, 138, 2676-2676.	1.4	1
40	Modified Delphi Method Identifies Consensus Areas for Routine Minimal Residual Disease Testing in Multiple Myeloma. Blood, 2021, 138, 1631-1631.	1.4	0
41	Clinical features and diagnosis of multiple myeloma: a population-based cohort study in primary care. BMJ Open, 2021, 11, e052759.	1.9	9
42	Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis. Leukemia and Lymphoma, 2020, 61, 668-679.	1.3	5
43	In-house age-specific reference ranges for free light chains measured on the SPAPlusÂ® analyser. Annals of Clinical Biochemistry, 2020, 57, 138-143.	1.6	3
44	Carfilzomib therapy for relapsed myeloma: results of a UK multicentre experience. British Journal of Haematology, 2020, 188, e57-e60.	2.5	2
45	Clinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma. Leukemia and Lymphoma, 2020, 61, 732-736.	1.3	3
46	Potential â€˜significanceâ€™ of monoclonal gammopathy of â€˜undetermined significanceâ€™ during COVID-19 pandemic. Blood Cells, Molecules, and Diseases, 2020, 85, 102481.	1.4	8
47	Realâ€world treatment patterns and outcomes in nonâ€transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom. European Journal of Haematology, 2020, 105, 308-325.	2.2	11
48	Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care. Haematologica, 2020, 105, e474-479.	3.5	10
49	Realâ€world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVIDâ€19 disease) in patients with multiple myeloma receiving systemic antiâ€cancer therapy. British Journal of Haematology, 2020, 190, e83-e86.	2.5	92
50	Myeloma care adaptations in the UK during SARSâ€CoVâ€2 pandemic: Challenges and measurable outcomes. European Journal of Haematology, 2020, 105, 662-666.	2.2	2
51	Time to Redefine Risk-Stratification and Response Criteria in Immunoglobulin Light Chain Amyloidosis?. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e769-e776.	0.4	2
52	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer Journal, 2020, 10, 17.	6.2	75
53	Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients. PLoS ONE, 2020, 15, e0229469.	2.5	7
54	Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Annals of Hematology, 2020, 99, 1049-1061.	1.8	31

#	Article	IF	Citations
55	DPACEâ€based chemotherapy in the era of myeloma novel agents: A UK multicentre study. European Journal of Haematology, 2020, 105, 231-233.	2.2	2
56	Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. Leukemia, 2020, 34, 3019-3027.	7.2	17
57	Evolving Role of Daratumumab: From Backbencher to Frontline Agent. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 572-587.	0.4	15
58	Open Label, Multicenter, Dose-Escalation/ Expansion Phase Ib Study to Evaluate Safety and Activity of BET Inhibitor RO6870810 (RO), Given As Monotherapy to Patients (pts) with Advanced Multiple Myeloma. Blood, 2020, 136, 12-14.	1.4	4
59	Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated Outside the Clinical Trial Setting Via an Early Access Program (EAP) in Europe: Second Interim Analysis of the 'Use Via Early Access to Ixazomib' (UVEA-IXA) Study. Blood, 2020, 136, 42-44.	1.4	4
60	Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2020, 136, 47-48.	1.4	11
61	First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2020, 38, 8500-8500.	1.6	40
62	Pharmacodynamic (PD) responses drive dose/schedule selection of CC-92480, a novel CELMoD agent, in a phase 1 dose-escalation study in relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2020, 38, 8531-8531.	1.6	3
63	Bone Pain As a Presenting Symptom in Patients with Newly Diagnosed Multiple Myeloma in the Primary Care Setting: A Population-Based Cohort Study. Blood, 2020, 136, 18-18.	1.4	0
64	Quality of Life Data from a Prospective Randomised Trial of Newly Diagnosed Myeloma Patients with Renal Failure: Optimal Trial. Blood, 2020, 136, 5-6.	1.4	0
65	Prospective Study Reveals Increased Platelet Function Associated with Multiple Myeloma and Its Treatment. Blood, 2020, 136, 21-21.	1.4	0
66	Resource implications of bortezomib therapy in a large UK cohort: An evaluation study. Journal of Oncology Pharmacy Practice, 2019, 25, 1995-1998.	0.9	0
67	Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs. Journal of Bone Oncology, 2019, 17, 100243.	2.4	15
68	Long-term clinical outcomes in a cohort of patients with solitary plasmacytoma treated in the modern era. PLoS ONE, 2019, 14, e0219857.	2.5	13
69	Reducing infection-related morbidity and mortality in patients with myeloma. Lancet Oncology, The, 2019, 20, 1633-1635.	10.7	3
70	Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease. Nature Communications, 2019, 10, 4533.	12.8	46
71	Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment. Scientific Reports, 2019, 9, 14189.	3.3	14
72	Long term outcomes in monoclonal gammopathy of renal significance. British Journal of Haematology, 2019, 186, 706-716.	2.5	14

#	Article	IF	Citations
73	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 781-794.	10.7	254
74	Testing and management for monoclonal gammopathy of uncertain significance and myeloma patients presenting with osteoporosis and fragility fractures. Rheumatology, 2019, 58, 1142-1153.	1.9	7
75	PS1411 CHARACTERISTICS AND TREATMENT OUTCOMES OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) NONâ€STEM CELL TRANSPLANT (NSCT) PATIENTS IN THE UK, GERMANY, AND FRANCE. HemaSphere, 2019, 3, 648-649.	2.7	0
76	Pathophysiology and management of monoclonal gammopathy of renal significance. Blood Advances, 2019, 3, 2409-2423.	5.2	48
77	Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) Delivers a Reduction and Delay in Worsening of Pain Symptoms for Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplant. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e225-e226.	0.4	0
78	Consolidation following DPACE therapy improves outcomes in relapsed/refractory myeloma patients in the era of novel agents. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e254-e255.	0.4	0
79	PF599 EFFICACY OF BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH CARFILZOMIB-REFRACTORY MYELOMA IN THE UK NCRI CARDAMON TRIAL. HemaSphere, 2019, 3, 252-253.	2.7	1
80	PF603 FASTER & SUSTAINED IMPROVEMENT IN HEALTHâ€RELATED QUALITY OF LIFE IN TRANSPLANTâ€INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PTS TREATED WITH DARATUMUMAB, LENALIDOMIDE & DEXAMETHASONE (Dâ€RD) VS RD: MAIA. HemaSphere, 2019, 3, 255.	2.7	0
81	PB2117ÂPOMALIDOMIDE PLUS LOWâ€DEXAMETHASONE TREATMENT FOR â‰¥ 1 YEAR IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT: A SUBANALYSIS OF THE MMâ€013ÂPHASE 2 STUDY. HemaSphere, 2019, 3, 953.	2.7	0
82	Pomalidomide and Dexamethasone Treatment for â‰¥ 1 Year in Renally Impaired Patients With Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e284-e285.	0.4	0
83	Serological normalisation as a surrogate marker for minimal residual disease negativity in multiple myeloma. British Journal of Haematology, 2019, 185, 775-778.	2.5	2
84	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 393, 253-264.	13.7	187
85	Efficacy and Safety of Carfilzomib at 56mg/m2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study. Blood, 2019, 134, 861-861.	1.4	7
86	Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA.. Journal of Clinical Oncology, 2019, 37, 8016-8016.	1.6	7
87	PF629 CONSOLIDATION FOLLOWING INFUSIONAL DPACE IMPROVES OUTCOMES IN NOVEL AGENT RELAPSED/REFRACTORY MYELOMA PATIENTS. HemaSphere, 2019, 3, 267-268.	2.7	0
88	PS1388 RELATIVE EFFICACY OF APPROVED AND RECENTLY INTRODUCED TREATMENTS FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: A NETWORK META-ANALYSIS. HemaSphere, 2019, 3, 636.	2.7	1
89	PS1416 EVOLVING TREATMENT PATTERNS IN NON-STEM CELL TRANSPLANT (NSCT) NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): RESULTS FROM A REAL-WORLD CHART REVIEW IN FRANCE, GERMANY, AND THE UK. HemaSphere, 2019, 3, 651.	2.7	0
90	PS1382 DEEPENING RESPONSES SEEN WITH IXAZOMIB MAINTENANCE POSTâ€AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) ARE ASSOCIATED WITH PROLONGED PROGRESSIONâ€FREE SURVIVAL â€“ ANALYSIS FROM THE TOURMALINEâ€MM3 STUDY. HemaSphere, 2019, 3, 632-633.	2.7	0

#	Article	IF	Citations
91	Optimal - a Study of Bortezomib, Bendamustine and Dexamethasone (BBD) Vs Thalidomide, Bendamustine and Dexamethasone (BTD) in Patients with Renal Failure Defined As an Egfr below 30 Mls/Min. Blood, 2019, 134, 3135-3135.	1.4	2
92	Clinical-Grade Whole Genome Sequencing Reproduces FISH Cytogenetics and Provides Actionable Data in Newly Diagnosed Myeloma - a Pilot Study from the UK 100,000 Genomes Project. Blood, 2019, 134, 3062-3062.	1.4	1
93	Infection-Related Morbidity Reduced Overall Survival in a Large Real-World Cohort of Transplant Ineligible Newly Diagnosed Myeloma Patients Treated with UK Standard of Care. Blood, 2019, 134, 4768-4768.	1.4	0
94	Treat or palliate: outcomes of very elderly myeloma patients. Haematologica, 2018, 103, e32-e34.	3.5	15
95	Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. Journal of Clinical Oncology, 2018, 36, 2035-2043.	1.6	55
96	Clinical outcomes of bortezomib-based therapy in myeloma. PLoS ONE, 2018, 13, e0208920.	2.5	4
97	Quantifying intervals to diagnosis in myeloma: a systematic review and meta-analysis. BMJ Open, 2018, 8, e019758.	1.9	26
98	Single Cell Analysis of Acquired Pomalidomide-Resistance in Multiple Myeloma Cell Lines Reveals Distinct Subclonal Cereblon Mutations and Gene Expression Heterogeneity. Blood, 2018, 132, 2648-2648.	1.4	1
99	Relative Efficacy of Treatment Options in Newly Diagnosed Multiple Myeloma: Results from a Systematic Literature Review and Network Meta-Analysis. Blood, 2018, 132, 4744-4744.	1.4	1
100	Elective Vs Non-Elective Hospital Admissions By Patients with Multiple Myeloma in England 2014 - 2018. Blood, 2018, 132, 4743-4743.	1.4	1
101	Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease. Blood, 2018, 132, 802-802.	1.4	6
102	Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study. Blood, 2018, 132, 306-306.	1.4	3
103	Estimating the Effect of Individual Agents in the Treatment of Relapsed, Refractory Multiple Myeloma (RRMM). Blood, 2018, 132, 2013-2013.	1.4	0
104	Multiple Myeloma Treatment Is Associated with Enhanced Platelet Reactivity. Blood, 2018, 132, 3300-3300.	1.4	2
105	Realâ€world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multiâ€centre <scp>UK</scp> experience. British Journal of Haematology, 2017, 176, 908-917.	2.5	25
106	Living with the burden of relapse in multiple myeloma from the patient and physician perspective. Leukemia Research, 2017, 59, 75-84.	0.8	30
107	Dhalion. Proceedings of the VLDB Endowment, 2017, 10, 1825-1836.	3.8	106
108	Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study. Blood, 2017, 130, 835-835.	1.4	6

#	Article	IF	Citations
109	Durvalumab (DURVA) plus daratumumab (DARA) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2017, 35, TPS8054-TPS8054.	1.6	2
110	Multiple myeloma in the very elderly patient: challenges and solutions. Clinical Interventions in Aging, 2016, 11, 423.	2.9	28
111	Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma. Biology of Blood and Marrow Transplantation, 2016, 22, 1926-1937.	2.0	16
112	Hevylite and Freelite Normalisation Is a Surrogate Marker for MRD Negativity Post-ASCT. Blood, 2016, 128, 4633-4633.	1.4	2
113	Transcriptome Profiling of the Myeloma-Bone Niche Identifies BMP Signaling Role in Bone Destruction and Niche Maintenance, and Potential As a Therapeutic Target. Blood, 2016, 128, 483-483.	1.4	0
114	Long Term Outcomes in Monoclonal Gammopathy of Renal Significance (MGRS). Blood, 2016, 128, 5948-5948.	1.4	0
115	Safety Results of a Phase 2 Multicenter, Open-Label Study of Pomalidomide (CC-4047) Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment. Blood, 2016, 128, 3311-3311.	1.4	0
116	Optimizing the management of patients with spinal myeloma disease. British Journal of Haematology, 2015, 171, 332-343.	2.5	25
117	Time to redefine Myeloma. British Journal of Haematology, 2015, 171, 1-10.	2.5	18
118	Managing multiple myeloma in the over 70s: A review. Maturitas, 2015, 80, 148-154.	2.4	6
119	Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide. Annals of Hematology, 2015, 94, 643-649.	1.8	13
120	Safety of Treatment (Tx) with Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI), Including Those on Dialysis. Blood, 2015, 126, 374-374.	1.4	6
121	Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs. PLoS ONE, 2015, 10, e0136207.	2.5	10
122	Serum-free light-chain assay: clinical utility and limitations. Annals of Clinical Biochemistry, 2014, 51, 528-542.	1.6	59
123	Bendamustine, thalidomide and dexamethasone is an effective salvage regimen for advanced stage multiple myeloma - response to Grey-Davies etÂal. British Journal of Haematology, 2012, 156, 555-555.	2.5	0
124	Fluorescenceâ€based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells. British Journal of Haematology, 2012, 157, 564-579.	2.5	17
125	Rituximab and thalidomide combination therapy for Castleman disease. British Journal of Haematology, 2012, 158, 421-423.	2.5	25
126	Beta7 Integrins Regulate Podia Formation in Multiple Myeloma (MM) Cells for the Interaction with the Cellular and Non-Cellular Bone Marrow (BM) Stroma. Blood, 2012, 120, 3979-3979.	1.4	0

#	Article	IF	Citations
127	Alemtuzumab-Based Reduced-Intensity Conditioning Allogeneic Transplantation for Myeloma and Plasma Cell Leukemia â€“ A Single-Institution Experience. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 242-245.	0.4	4
128	Pomalidomide therapy for myeloma. Expert Opinion on Investigational Drugs, 2011, 20, 691-700.	4.1	29
129	Mott cells in CD20-positive myeloma. British Journal of Haematology, 2011, 152, 366-366.	2.5	0
130	Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. British Journal of Haematology, 2011, 155, 632-634.	2.5	39
131	Podia in Multiple Myeloma (MM) Cells Promote Adhesion with Bone Marrow (BM) Fibroblastic Stromal Cells. Blood, 2011, 118, 626-626.	1.4	1
132	The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. British Journal of Haematology, 2010, 150, 326-333.	2.5	57
133	Direct Effect on the Stroma by the Conventional Anti-Multiple Myeloma Drug Dexamethasone Results In Resistance of Multiple Myeloma Plasma Cells Against Therapy. Sensitisation to Dexamethasone by the Kinase Inhibitor Dasatinib. Blood, 2010, 116, 1931-1931.	1.4	1
134	Novel In Vitro Experimental Platform for High Throughput Analysis of the Effect of Drugs on Multiple Myeloma Cells and the Tumour Microenvironment In a Co-Culture Setting. Blood, 2010, 116, 982-982.	1.4	0
135	Acute myeloid leukaemia presenting with mediastinal myeloid sarcoma: Report of three cases and review of literature. Leukemia and Lymphoma, 2007, 48, 290-294.	1.3	19
136	Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. British Journal of Haematology, 2007, 137, 374-375.	2.5	38
137	Circulating DNA: a potential marker of sickle cell crisis. British Journal of Haematology, 2007, 139, 331-336.	2.5	19
138	Progression Free Survival (PFS) in Alemtuzumab Based RIC Allogeneic Transplantation for Myeloma Is Improved with Use of Pre-Emptive DLI (pDLI).. Blood, 2007, 110, 3034-3034.	1.4	0
139	Incidence and management of hepatic venoocclusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT). Bone Marrow Transplantation, 2006, 38, 823-824.	2.4	26
140	Disseminated herpes virus (HSV-2) infection with rhabdomyolysis and hemophagocytic lymphohistiocytosis in a patient with bone marrow failure syndrome. Annals of Hematology, 2006, 85, 629-630.	1.8	17
141	Bevacizumab Therapy for POEMS Syndrome.. Blood, 2006, 108, 5108-5108.	1.4	0
142	Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone. Haematologica, 2006, 91, ECR44.	3.5	14
143	Ambulatory therapy of patients with free-floating proximal deep vein thrombosis is safe. Thrombosis and Haemostasis, 2005, 94, 1343-1344.	3.4	2
144	Haemophagocytic Lymphohistiocytosis Post Liver Transplantation.. Blood, 2004, 104, 3822-3822.	1.4	0

#	Article	IF	Citations
145	Castlemanâ€™s disease. , 0, , 216-224.		0